Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.857
Filtrar
1.
Exp Parasitol ; 208: 107802, 2020 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-31730782

RESUMO

In insects, diet plays an important role in growth and development. Insects can vary their diet composition based on their physiological needs. In this study we tested the influence of diet composition involving varying concentrations of macronutrients and zinc on the immune-tolerance following parasite and pathogen exposure in Spodoptera litura larvae. We also tested the insecticidal potential of Mesorhabditis belari, Enterobacter hormaechei and its secondary metabolites on Spodoptera litura larvae. The results shows macronutrient composition does not directly affect the larval tolerance to nematode infection. However, Zinc supplemented diet improved the immune tolerance. While larvae exposed to bacterial infection performed better on carbohydrate rich diet. Secondary metabolites from bacteria produced an immune response in dose dependent mortality. The study shows that the larvae maintained on different diet composition show varied immune tolerance which is based on the type of infection.


Assuntos
Enterobacter/fisiologia , Controle Biológico de Vetores , Rhabditoidea/fisiologia , Spodoptera/imunologia , Análise de Variância , Animais , Bioensaio , Carboidratos/administração & dosagem , Cromatografia Líquida de Alta Pressão , Dieta , Enterobacter/imunologia , Enterobacter/patogenicidade , Cromatografia Gasosa-Espectrometria de Massas , Tolerância Imunológica , Larva/imunologia , Dose Letal Mediana , Proteínas/administração & dosagem , Rhabditoidea/imunologia , Rhabditoidea/patogenicidade , Espectroscopia de Infravermelho com Transformada de Fourier , Spodoptera/fisiologia , Simbiose , Virulência , Zinco/administração & dosagem
2.
Chem Commun (Camb) ; 55(99): 14930-14933, 2019 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-31769770

RESUMO

A dual responsive NIRF turn-on protein delivery system incorporating an NIRF turn-on probe and protein into one single nanoparticle has been constructed. It can be taken up efficiently by A549 cells, where protein release and NIRF recovery happen simultaneously in response to low pH and excessive H2O2. This work provides a novel system for monitoring intracellular protein delivery.


Assuntos
Nanopartículas , Proteínas/administração & dosagem , Microambiente Tumoral , Células A549 , Humanos , Peróxido de Hidrogênio/metabolismo , Concentração de Íons de Hidrogênio , Sondas Moleculares , Proteínas/metabolismo
3.
Toxicol Lett ; 317: 120-129, 2019 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-31580884

RESUMO

PEGylation is considered a safe mechanism to enhance the pharmacokinetics (PK) and pharmacodynamics (PD) of biotherapeutics. Previous studies using PEGylation as a PK enhancement tool have reported benign PEG-related vacuolation in multiple tissues. This paper establishes a threshold for PEG burden beyond which there are alterations in tissue architecture that could potentially lead to dysfunction. As part of the nonclinical safety assessment of Compound A, a 12 kDa protein conjugated to a 40 kDa branched PEG molecule, monkeys were dosed subcutaneously twice weekly for 3 months at protein doses resulting in weekly PEG doses of 8, 24, 120, or 160 mg/kg. Consistent with previous reports with PEGylated biomolecules, Compound A administration resulted in intracellular vacuoles attributed to the PEG moiety in macrophages in numerous tissues and epithelial cells in the choroid plexus and kidney. Vacuolation occurred at all doses with dose-dependent severity and no evidence of recovery up to 2 months after dosing cessation. The vacuolation was considered nonadverse at PEG doses ≤120 mg/kg/week. However, at 160 mg/kg/week PEG, the vacuolation in choroid plexus, pituitary gland, kidney, and choroid of the eye was considered adverse due to significant alterations of tissue architecture that raised concern for the possibility of compromised tissue function. To our knowledge, this is the first report of potentially adverse cellular consequences of PEG accumulation in tissues other than kidney. Furthermore, the lack of reversibility of vacuolation coupled with the lack of a biomarker for intracellular PEG accumulation highlights a potential risk that should be weighed against the benefits of PK/PD enhancement for long-term administration of PEGylated compounds at high doses.


Assuntos
Células Epiteliais/efeitos dos fármacos , Macrófagos/efeitos dos fármacos , Polietilenoglicóis/toxicidade , Proteínas/toxicidade , Vacúolos/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Esquema de Medicação , Composição de Medicamentos , Células Epiteliais/patologia , Feminino , Injeções Subcutâneas , Macaca fascicularis , Macrófagos/patologia , Masculino , Polietilenoglicóis/administração & dosagem , Proteínas/administração & dosagem , Medição de Risco , Fatores de Tempo , Vacúolos/patologia
4.
Food Funct ; 10(9): 5574-5586, 2019 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-31432066

RESUMO

The antidiabetic activity and potential underlying mechanism of a polysaccharide-protein (PSP) complex from Corbicula fluminea were determined in streptozotoxin (STZ)-induced diabetic rats. PSP exhibited inhibitory activity (in vitro) against α-glucosidase and α-amylase via a reversible competitive inhibition pattern with a stronger inhibition for α-glucosidase. Dietary administration of PSP had potential antidiabetic activities in vivo, which was evidenced by the fact that PSP alleviates body weight loss and organ injuries, reduced fasting blood glucose levels, elevated glucose tolerance, and ameliorated lipid metabolism and hepatic functions, as well as attenuated oxidative stress in STZ-treated diabetic rats. Furthermore, our results demonstrated that the antidiabetic activities of PSP were associated with the activation of the phosphoinositide 3-kinase/protein kinase B signaling pathway in STZ-treated rats. These findings supported the potential of PSP to be used as a functional ingredient in the preparation of functional and medicinal foods to inhibit diabetes mellitus and its complications.


Assuntos
Corbicula/química , Diabetes Mellitus Experimental/tratamento farmacológico , Hipoglicemiantes/administração & dosagem , Polissacarídeos/administração & dosagem , Proteínas/administração & dosagem , Animais , Glicemia/metabolismo , Diabetes Mellitus Experimental/enzimologia , Diabetes Mellitus Experimental/metabolismo , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Estresse Oxidativo/efeitos dos fármacos , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Ratos , Ratos Sprague-Dawley , Estreptozocina , alfa-Glucosidases/metabolismo
5.
Int J Biol Macromol ; 138: 556-564, 2019 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-31336116

RESUMO

Native and acetylated broken-rice starches (nanocrystals) with different degrees of substitution (DS) and their corresponding films were individually prepared, and the drug release profiles, weight loss, solubility and dispersion and surface morphology were comparatively studied. Bovine serum albumin (BSA) was used as a model drug. Acetylated native starch (ANS) DS 2.58, acetylated starch nanocrystals (ASN) DS 0.98, ASN DS 1.86, and ASN DS 2.72 were observed to be very soluble in chloroform. BSA was released rapidly from the native rice starch (NS) and ANS DS 2.58 films. ASN with high DS significantly slowed down the release of BSA from films, the percentages of BSA released from film ASN DS 2.72 only reached to 13% after 3.5 weeks release, and the release data followed Korsmeyer-Peppas equation. Further studies reveal that the particle size of ASN DS 2.72 was smallest, and the weight loss of ASN DS 2.72 film was lowest. The results demonstrate that acetylation and nanometer particle form of rice starch film can effectively retard protein drug release, and the prepared films based on ASN with high DS from broken rice may be suitable for the controlled protein delivery.


Assuntos
Membranas Artificiais , Nanopartículas/química , Oryza/química , Proteínas/química , Amido/química , Acetilação , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Interações Hidrofóbicas e Hidrofílicas , Nanopartículas/ultraestrutura , Tamanho da Partícula , Proteínas/administração & dosagem , Solubilidade , Análise Espectral , Água/química
6.
J Orthop Surg Res ; 14(1): 199, 2019 Jul 02.
Artigo em Inglês | MEDLINE | ID: mdl-31266512

RESUMO

BACKGROUND: We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model. BPC 157, of which the LD1 has not been achieved, has been implemented as an anti-ulcer peptide in inflammatory bowel disease trials and recently in a multiple sclerosis trial. In animals, BPC 157 has an anti-inflammatory effect and therapeutic effects in functional recovery and the rescue of somatosensory neurons in the sciatic nerve after transection, upon brain injury after concussive trauma, and in severe encephalopathies. Additionally, BPC 157 affects various molecular pathways. METHODS: Therefore, BPC 157 therapy was administered by a one-time intraperitoneal injection (BPC 157 (200 or 2 µg/kg) or 0.9% NaCl (5 ml/kg)) 10 min after injury. The injury procedure involved laminectomy (level L2-L3) and a 60-s compression (neurosurgical piston (60-66 g) of the exposed dural sac of the sacrocaudal spinal cord). Assessments were performed at 1, 4, 7, 15, 30, 90, 180, and 360 days after injury. RESULTS: All of the injured rats that received BPC 157 exhibited consistent clinical improvement, increasingly better motor function of the tail, no autotomy, and resolved spasticity by day 15. BPC 157 application largely counteracted changes at the microscopic level, including the formation of vacuoles and the loss of axons in the white matter, the formation of edema and the loss of motoneurons in the gray matter, and a decreased number of large myelinated axons in the rat caudal nerve from day 7. EMG recordings showed a markedly lower motor unit potential in the tail muscle. CONCLUSION: Axonal and neuronal necrosis, demyelination, and cyst formation were counteracted. The functional rescue provided by BPC 157 after spinal cord injury implies that BPC 157 therapy can impact all stages of the secondary injury phase.


Assuntos
Fragmentos de Peptídeos/administração & dosagem , Proteínas/administração & dosagem , Recuperação de Função Fisiológica/efeitos dos fármacos , Traumatismos da Medula Espinal/tratamento farmacológico , Cicatrização/efeitos dos fármacos , Animais , Eletromiografia/métodos , Humanos , Vértebras Lombares , Masculino , Distribuição Aleatória , Ratos , Ratos Wistar , Recuperação de Função Fisiológica/fisiologia , Traumatismos da Medula Espinal/patologia , Cicatrização/fisiologia
7.
Nutr. hosp ; 36(extr.3): 49-52, jul. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-184435

RESUMO

Introducción: la fragilidad y la sarcopenia son dos condiciones altamente prevalentes en el adulto mayor que se solapan en diferentes vertientes del diagnóstico y del tratamiento. Objetivos: analizar la problemática nutricional relacionada con la fragilidad y la sarcopenia en personas de edad avanzada. Métodos: se ha realizado una revisión bibliográfica de las particularidades de la fragilidad y de la sarcopenia, así como del diagnóstico y del tratamiento nutricional. Resultados: la fragilidad es un síndrome geriátrico que puede identificarse si se tienen al menos tres de los siguientes criterios: pérdida de peso, fuerza de presión de la mano disminuida, velocidad de la marcha lenta, actividad física reducida y agotamiento. La sarcopenia es una enfermedad muscular que se caracteriza por una masa muscular baja y una fuerza muscular reducida como determinantes principales. Ambas condiciones pueden verse beneficiadas por un consumo adecuado de proteínas (1-1,5 g/kg/día) y una actividad física de resistencia regular. Conclusión: la identificación, prevención, seguimiento y tratamiento nutricional de la fragilidad y la sarcopenia en adultos mayores es de vital importancia dada su elevada prevalencia. El objetivo es mantener la integridad y minimizar la pérdida muscular en los adultos mayores. Un envejecimiento saludable incluye la realización de actividad física regular y el cumplimiento de los requerimientos proteicos de esta población


Introduction: frailty and sarcopenia are prevalent conditions in older adults which diagnosis and treatment often overlap. Objective: to analyze the nutritional problematic related to frailty and sarcopenia in older adults. Methods: a literature review, about particularities of frailty and sarcopenia, diagnosis and nutritional treatment, has been carried out. Results: frailty is a geriatric syndrome that can be identified by at least three of the following criteria: weight loss, exhaustion, reduced physical activity, increased walk time, low grip strength. Sarcopenia is a muscular disease characterized by low muscle mass and reduced muscle strength as the main determinant. Both conditions can benefit from adequate protein intake (1-1.5 g/kg/day) and regular physical activity. Conclusion: identification, prevention, monitoring and nutritional treatment of frailty and sarcopenia in older adults is important because of its high prevalence. The main goal is to maintain the muscular integrity and minimize muscle loss in older adults. A healthy aging includes regular physical activity and the fulfillment of the protein requirements of this population


Assuntos
Humanos , Idoso , Idoso de 80 Anos ou mais , Idoso Fragilizado , Sarcopenia/dietoterapia , Transtornos Nutricionais/diagnóstico , Transtornos Nutricionais/terapia , Proteínas/administração & dosagem , Sarcopenia/diagnóstico , Sarcopenia/terapia , Atividade Motora , Suplementos Nutricionais
8.
Drug Dev Ind Pharm ; 45(9): 1403-1420, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31215293

RESUMO

The recent advances in pharmaceutical industry in the area of drug delivery and development have resulted into wide variety of biomolecules, particularly peptides and proteins, to palliate the treatment for severe diseases. The rampant development of peptides and proteins in industry mandate the understanding of their characteristic nature and developability. Despite their therapeutic potential, peptides and proteins pose complex challenges in drug delivery and require scientist to contemplate to achieve suitable delivery system. As most of the commercial products for proteins and peptides are available as a parenteral delivery and freeze drying process is one commonly used technique, it is imperative to understand the complex steps of development for better and faster product development. This review provides an overview of the stability and formulation development for peptides and proteins. The most common route for protein delivery, parenteral, has been focused on parenteral solution and lyophilization as formulation strategy. Additionally, new drug delivery and half-life extension approaches will further the reach of this unique class of molecules. Efforts are underway to explore the area with new technologies and development.


Assuntos
Composição de Medicamentos/métodos , Sistemas de Liberação de Medicamentos/métodos , Desenvolvimento de Medicamentos , Peptídeos/administração & dosagem , Proteínas/administração & dosagem , Administração por Inalação , Química Farmacêutica , Estabilidade de Medicamentos , Excipientes/química , Liofilização , Meia-Vida , Humanos , Infusões Parenterais , Injeções , Peptídeos/química , Peptídeos/farmacocinética , Proteínas/química , Proteínas/farmacocinética
9.
PLoS One ; 14(6): e0218887, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31233553

RESUMO

INTRODUCTION: Aggressive nutritional strategy, particularly enhancing early provision of energy and protein, has appeared to reduce postnatal growth failure and improve later developmental outcomes. But the amount of macronutrients required remains unclear. The aim of this study was to investigate the impact of protein and energy intakes during the first two weeks after birth on neurodevelopmental outcomes. METHODS: This retrospective cohort study of very low birth weight infants born between January 2012 and December 2015 was conducted at one tertiary neonatal intensive care unit. The primary outcome was a neurodevelopmental impairment (NDI) at 2 years corrected age defined by a cerebral palsy or a 24 month Ages and Stages Questionnaires score on any of the five domains lower than 2 standard deviation below the mean score. Multivariable logistic regression analysis was used to adjust for perinatal and postnatal confounders. RESULTS: Among 245 (73%) infants discharged home alive, 159 (65%) had follow-up at 2 years. Infants with NDI (55/159, 35%) were more likely male gender (67.3% versus 46.2%, P = 0.02) and experienced more patent ductus arteriosus (PDA) ligation (20% versus 5.8%, P = 0.01) than control. After adjusting for confounders, first-week protein intake (OR: 2.27 [CI: 1.07-5.14]; P < 0.05), second-week non-protein energy intake (OR: 1.03 [CI: 1.01-1.05]; P < 0.01) and PDA ligation (OR: 6.81 [1.80-28.46]; P < 0.01) had significant independent association with higher likelihood of NDI at 2 years. CONCLUSION: Providing nutrition above the optimal level may not be beneficial and may even be harmful. These results confirm the recent recommendation to decrease amino acid intakes published in the latest ESPGHAN guidelines.


Assuntos
Ingestão de Energia/fisiologia , Recém-Nascido de muito Baixo Peso/crescimento & desenvolvimento , Sistema Nervoso/crescimento & desenvolvimento , Proteínas/administração & dosagem , Pré-Escolar , Permeabilidade do Canal Arterial/fisiopatologia , Feminino , Seguimentos , Idade Gestacional , Humanos , Lactente , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Ligadura , Masculino , Estudos Retrospectivos
10.
J Pharmacol Exp Ther ; 370(3): 671-681, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31040175

RESUMO

The unique anticancer, biochemical, and immunologic properties of nanomaterials are becoming a new tool in biomedical research. Their translation into the clinic promises a new wave of targeted therapies. One nanomaterial of particular interest are zinc oxide (ZnO) nanoparticles (NPs), which has distinct mechanisms of anticancer activity including unique surface, induction of reactive oxygen species, lipid oxidation, pH, and also ionic gradients within cancer cells and the tumor microenvironment. It is recognized that ZnO NPs can serve as a direct enzyme inhibitor. Significantly, ZnO NPs inhibit extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) associated with melanoma progression, drug resistance, and metastasis. Indeed, direct intratumoral injection of ZnO NPs or a complex of ZnO with RNA significantly suppresses ERK and AKT phosphorylation. These data suggest ZnO NPs and their complexes or conjugates with nucleic acid therapeutic or anticancer protein may represent a potential new strategy for the treatment of metastatic melanoma, and potentially other cancers. This review focuses on the anticancer mechanisms of ZnO NPs and what is currently known about its biochemical effects on melanoma, biologic activity, and pharmacokinetics in rodents and its potential for translation into large animal, spontaneously developing models of melanoma and other cancers, which represent models of comparative oncology.


Assuntos
Sistemas de Liberação de Medicamentos/métodos , Oncologia/tendências , Nanomedicina/tendências , Nanoestruturas/administração & dosagem , Neoplasias/tratamento farmacológico , Ácidos Nucleicos/administração & dosagem , Ácidos Nucleicos/uso terapêutico , Proteínas/administração & dosagem , Proteínas/uso terapêutico , Óxido de Zinco/administração & dosagem , Animais , Humanos , Nanoestruturas/química , Metástase Neoplásica , Óxido de Zinco/química
11.
Ultrason Sonochem ; 55: 86-95, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-31084795

RESUMO

Delivery of drugs and active agents to human skin by formulation containing nanosystems have shown remarkable advance in recent nanotechnology research. The aim of current investigation is to study protein drug, extracted from medicinal leech tissue and evaluate an isotropic and kinetically stable nanoemulsion formulation, with least surfactant and co-surfactant concentrations also with optimal solubility and stability, for topical delivery. It is a fact that physical properties of oil phase has an impact on nanoemulsion formation and stabilization. In this research, various factors, such as oil types (olive oil and sesame oil) and oil content for their effects on particle size and stability of protein nanoemulsion were first investigated. Secondly, optimized formulation of protein nanoemulsion was characterized by droplet size and zeta potential analysis, Transmission electron microscopy (TEM), viscosity, pH, and refractive index. Thirdly, stability studies were done to select the best formulation. The results of our experiments showed that an increase in the concentration of olive oil and sesame oil led to a nanoemulsion with smaller size of droplets and with higher stability, respectively. However; slight variations in droplet size were observed in case of nanoemulsion with olive oil. As a result of various experiments, a Nanoemulsion with 25% olive oil was selected as optimized formulation owing to its much smaller droplet size (143.1 nm), lower polydispersity index, higher zeta potential (-33.3 mV). No considerable changes in droplet size, viscosity and pH occurred during a 30-day storage period at 4 °C. This procedure also suggested that our selected nanoemulsion was physically stable. Additionally, TEM revealed that particles were morphologically spherical. In conclusion, our analyses of the experiments proved the fact that nanoemulsions are promising novel formulations for protein drugs and can greatly enhance stability of protein drugs.


Assuntos
Portadores de Fármacos/química , Nanopartículas/química , Óleos/química , Proteínas/química , Ondas Ultrassônicas , Água/química , Administração Tópica , Técnicas de Química Sintética , Portadores de Fármacos/síntese química , Emulsões , Tamanho da Partícula , Proteínas/administração & dosagem , Proteínas/uso terapêutico
12.
AAPS PharmSciTech ; 20(5): 190, 2019 May 20.
Artigo em Inglês | MEDLINE | ID: mdl-31111296

RESUMO

Protein and peptide drugs have many advantages, such as high bioactivity and specificity, strong solubility, and low toxicity. Therefore, the strategies for improving the bioavailability of protein peptides are reviewed, including chemical modification of nanocarriers, absorption enhancers, and mucous adhesion systems. The status, advantages, and disadvantages of various strategies are systematically analyzed. The systematic and personalized design of various factors affecting the release and absorption of drugs based on nanoparticles is pointed out. It is expected to design a protein peptide oral delivery system that can be applied in the clinic.


Assuntos
Sistemas de Liberação de Medicamentos , Nanopartículas/administração & dosagem , Peptídeos/administração & dosagem , Proteínas/administração & dosagem , Administração Oral , Desenho de Fármacos , Humanos
13.
Chem Asian J ; 14(13): 2193-2202, 2019 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-31125182

RESUMO

DNA nanotechnology has been employed in the construction of self-assembled nano-biomaterials with uniform size and shape for various biological applications, such as bioimaging, diagnosis, or therapeutics. Herein, recent successful efforts to utilize multifunctional DNA origami nanoplatforms as drug-delivery vehicles are reviewed. Diagnostic and therapeutic strategies based on gold nanorods, chemotherapeutic drugs, cytosine-phosphate-guanine, functional proteins, gene drugs, and their combinations for optoacoustic imaging, photothermal therapy, chemotherapy, immunological therapy, gene therapy, and coagulation-based therapy are summarized. The challenges and opportunities for DNA-based nanocarriers for biological applications are also discussed.


Assuntos
DNA/química , Portadores de Fármacos/química , Nanoestruturas/química , Nanotecnologia/métodos , Animais , Sistemas de Liberação de Medicamentos/métodos , Humanos , Nanoestruturas/ultraestrutura , Oligodesoxirribonucleotídeos/administração & dosagem , Preparações Farmacêuticas/administração & dosagem , Proteínas/administração & dosagem
14.
J Nanobiotechnology ; 17(1): 48, 2019 Apr 03.
Artigo em Inglês | MEDLINE | ID: mdl-30943985

RESUMO

Nanoparticles (NPs) are atomic clusters of crystalline or amorphous structure that possess unique physical and chemical properties associated with a size range of between 1 and 100 nm. Their nano-sized dimensions, which are in the same range as those of vital biomolecules, such as antibodies, membrane receptors, nucleic acids, and proteins, allow them to interact with different structures within living organisms. Because of these features, numerous nanoparticles are used in medicine as delivery agents for biomolecules. However, off-target drug delivery can cause serious side effects to normal tissues and organs. Considering this issue, it is essential to develop bioengineering strategies to significantly reduce systemic toxicity and improve therapeutic effect. In contrast to passive delivery, nanosystems enable to obtain enhanced therapeutic efficacy, decrease the possibility of drug resistance, and reduce side effects of "conventional" therapy in cancers. The present review provides an overview of the most recent (mostly last 3 years) achievements related to different biomolecules used to enable targeting capabilities of highly diverse nanoparticles. These include monoclonal antibodies, receptor-specific peptides or proteins, deoxyribonucleic acids, ribonucleic acids, [DNA/RNA] aptamers, and small molecules such as folates, and even vitamins or carbohydrates.


Assuntos
Antineoplásicos/administração & dosagem , Portadores de Fármacos/química , Nanocompostos/química , Animais , Anticorpos Monoclonais/administração & dosagem , Aptâmeros de Nucleotídeos/administração & dosagem , Liberação Controlada de Fármacos , Resistencia a Medicamentos Antineoplásicos , Terapia Genética , Humanos , Terapia de Alvo Molecular , Nanomedicina , Ácidos Nucleicos/administração & dosagem , Proteínas/administração & dosagem
16.
Nanomedicine (Lond) ; 14(7): 871-887, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30895865

RESUMO

AIM: To provide multilayered combination therapies encompassing nanoparticles and organic peptides and to assess their efficacy in the treatment of arthritis. MATERIALS & METHODS: Fish oil protein (FP) was isolated from fish oil glands and tagged with spherical gold nanoparticles (GNPs). Tagged GNPs were encapsulated in DPPC liposomes (FP-GNP-DPPC) and characterized. RESULTS & CONCLUSION: FP increased the hydrophilicity of GNP, while encapsulation of FP-GNP within liposomes increased the hydrophobicity. In vitro release studies of FP-GNP-DPPC exhibited sustained release of FP in simulated synovial fluid. FP-GNP-DPPC injected into intra-articular joints of rats displayed anti-osteoarthritic effects in osteoarthritic rat model. This is the first study to report the anti-osteoarthritic activity of FP and DPPC encapsulated FP-GNP liposomes.


Assuntos
Óleos de Peixe/química , Ouro/química , Articulações/efeitos dos fármacos , Nanopartículas Metálicas/química , Osteoartrite/tratamento farmacológico , Proteínas/administração & dosagem , Animais , Apoptose/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Cordados , Portadores de Fármacos/química , Liberação Controlada de Fármacos , Humanos , Interações Hidrofóbicas e Hidrofílicas , Lipossomos/química , Tamanho da Partícula , Fosfolipídeos/química , Proteínas/farmacologia , Ratos Wistar , Propriedades de Superfície
17.
Methods Mol Biol ; 1922: 121-128, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30838570

RESUMO

Multiwalled carbon nanotubes (MWCNTs) are a particularly promising drug delivery system due to their high surface area allowing high-protein loading, their stability under biological conditions, and their unique interaction with cellular membranes. Studies have shown that covalent attachment of polyethylene glycol (PEG) improves biocompatibility and enhances surface hydrophilicity properties, suggesting that PEGylated MWCNTs are efficient and toxic-safe drug delivery systems. So far, CNTs are used for a broad range of applications in dentistry, especially for dental tissue repair and restorative. Here we present a protocol of protein immobilization onto MWCNTs and describe the procedure for delivering them into the cells after characterization of the nanotubes.


Assuntos
Sistemas de Liberação de Medicamentos/métodos , Nanotubos de Carbono/química , Proteínas/administração & dosagem , Endodontia Regenerativa/métodos , Polietilenoglicóis/química , Proteínas/uso terapêutico
18.
Bioconjug Chem ; 30(3): 515-524, 2019 03 20.
Artigo em Inglês | MEDLINE | ID: mdl-30839198

RESUMO

Cancer immunotherapy that induces a tumor-specific immune response for cancer eradication has received tremendous attention. To enhance the immunotherapeutic effects, many drug delivery strategies have been developed to overcome the physiological barriers as well as to reduce toxicity. For example, intratumoral or peritumoral administration of injectable depot formulations can directly target tumor sites for immunotherapy. Compared with systemic administration of therapeutics, this strategy has minimal side effects. Such local treatment can also trigger a systemic immune response for inhibiting tumor metastasis. This Topical Review highlights the recent studies on depot-mediated delivery of protein/peptide therapeutics for cancer immunotherapy. Further opportunities and challenges in this field are also discussed.


Assuntos
Imunoterapia/métodos , Neoplasias/terapia , Proteínas/administração & dosagem , Animais , Anticorpos/administração & dosagem , Anticorpos/uso terapêutico , Antígenos/administração & dosagem , Antígenos/uso terapêutico , Vacinas Anticâncer/administração & dosagem , Vacinas Anticâncer/uso terapêutico , Citocinas/administração & dosagem , Citocinas/uso terapêutico , Humanos , Proteínas/uso terapêutico
19.
Gerokomos (Madr., Ed. impr.) ; 30(1): 23-27, mar. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-182784

RESUMO

Objetivo: Conocer los resultados de las últimas publicaciones sobre sarcopenia en el anciano y el uso de complementos proteicos para su tratamiento y/o prevención. Metodología: Revisión sistemática sobre el uso de complementos proteicos en el tratamiento y prevención de la sarcopenia. La búsqueda se realizó en MEDLINE, Science Direct, SciELO, TRIP database y Dialnet. Se acotó al periodo 2011-2016. Se incluyeron ensayos clínicos aleatorizados y para valorar su calidad metodológica se usó la escala PEDro, seleccionando aquellos que tenían una puntuación igual o superior a 6. Resultados: El modo de aportar las proteínas en los 13 artículos revisados es muy variable. Estas se pueden dar diariamente, en 2-3 tomas, tras el ejercicio físico, generalmente de resistencia, con una frecuencia de 3-5 sesiones/semana. Las proteínas se suelen dar en forma de carne roja, queso, suero de leche o en estado puro, en cantidades que oscilan entre 20 y 45 g/día. Los aminoácidos esenciales rondan los 9 g/día y la leucina oscila entre 4 y 9 g/día. La suplementación con ß-hidroxi-ß-metilbutirato se encuentra entre 1,5-3,0 g/día. Estos aportes produjeron en general un aumento de la masa y la fuerza muscular, así como un incremento de la síntesis de proteínas musculoesqueléticas y del tamaño de la fibra muscular en el anciano. Conclusiones: En el enfoque terapéutico del síndrome de sarcopenia es fundamental la incorporación de proteínas de alto valor biológico a la dieta, que, junto al ejercicio de resistencia, van a tener un efecto sinérgico sobre el tejido muscular


Objective: To know the results of the latest researches on sarcopenia in the elderly and the use of protein supplements for their treatment and / or prevention. Methodology: Systematic review on the use of protein supplements in the treatment and prevention of sarcopenia. The search was carried out in MEDLINE, Science Direct, SciELO, TRIP database and Dialnet. It was limited to the period 2011/2016. Randomized clinical trials were included and PEDro scale was used to assess the methodological quality of them, including those with a score of 6 or higher. Results: The way to provide the proteins in the 13 articles reviewed is very variable. These can be given daily, times, after physical exercise, usually resistance, with a frequency of 3-5 sessions / week. Proteins are usually provided in the form of red meat, cheese, buttermilk or pure, in amounts ranging from 20-45 g / day. Essential amino acids are around 9 g / day and leucine ranges from 4-9 g / day. Supplementation with ß-hydroxy-ß-methylbutyrate is between 1.5-3.0 g / day. These contributions generally resulted in an increase in muscle mass and strength, as well as an increase in the synthesis of musculoskeletal proteins and muscle fiber size in the elderly. Conclusions: In the therapeutic approach of sarcopenia syndrome, it is essential the incorporation of proteins of high biological value into the diet, which, together with resistance exercise, are going to produce a synergistic effect on muscle tissue


Assuntos
Humanos , Idoso , Suplementos Nutricionais , Sarcopenia/prevenção & controle , Proteínas/administração & dosagem
20.
Biotechnol J ; 14(5): e1800530, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30810275

RESUMO

An ultrasound-responsive carrier for protein drugs is promising for site-specific release of proteins at disease sites in a designated time course because ultrasound readily penetrates deep into the interior of the body in a non-invasive way. However, the guideline for designing ultrasound-responsive carriers that are applicable to any protein remains to be established. Here, the aim is to develop an ultrasound-responsive material for the controlled release of a variety of proteins regardless of their charge and structure. The supramolecular polymeric hydrogel crosslinked with a host-guest interaction of ß-cyclodextrin and adamantane can enclose two kinds of model proteins and site-specifically and stepwisely release them in an ultrasound-guided manner without losing their activities. Furthermore, ultrasound-guided protein delivery to living cells is achieved on model tissue consisting of cells and extracellular matrix. The results of this study provide the proof of principle that the supramolecular polymeric hydrogel is applicable as the core carrier material in an ultrasound-guided protein delivery system.


Assuntos
Sistemas de Liberação de Medicamentos/métodos , Hidrogéis/química , Polímeros/química , Proteínas/administração & dosagem , Ondas Ultrassônicas , Materiais Biocompatíveis , Técnicas de Química Sintética , Recuperação de Fluorescência Após Fotodegradação , Células HeLa , Humanos , Muramidase , Proteínas/química , Proteínas/efeitos da radiação , beta-Ciclodextrinas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA